Headache
General Medicine · Topic 17
Source: NMC CBME Curriculum 2024 · Volume II · General Medicine · Topic 17 · combined PDF page 308
Practice questions
- An eligible adult presents to the emergency department with a migraine attack requiring parenteral therapy and has no contraindication to the treatment. According to the 2025 AHS evidence assessment, which therapy must be offered?
- For an eligible adult with an ED migraine attack requiring parenteral therapy, which nerve block carries a level A recommendation that it must be offered?
- Which parenteral drug does the 2025 AHS guideline state must not be offered to adults presenting to the ED with migraine?
- A patient with migraine requires parenteral ED treatment. Which option contains only therapies the 2025 AHS guideline says should be offered when appropriate (level B)?
- Which statement best reflects the 2025 AHS recommendation for intravenous paracetamol in adults treated for migraine in the ED?
- Which group consists entirely of therapies that may be offered (level C) for ED migraine when appropriate, according to the 2025 AHS guideline?
- A clinician notes that eptinezumab was considered likely effective in an ED evidence assessment. Which interpretation of the guideline's recommendation is most accurate?
- Which pairing correctly matches an intervention with its evidence category in the 2025 ED migraine assessment?
- An adult has episodic migraine and is considering pharmacologic prevention. Which pair had high-confidence evidence of greater efficacy than placebo in the updated systematic review?
- Which option lists only therapies with moderate-confidence evidence of benefit for episodic migraine prevention in the systematic review?
- For chronic migraine, which set of treatments had high-confidence evidence for reducing headache frequency in the systematic review?
- Which group contains only therapies with moderate-confidence evidence for reducing headache frequency in chronic migraine?
- A patient asks which therapies have evidence of improvement in validated patient-reported quality-of-life outcomes across episodic and chronic migraine populations. Which answer is supported by the systematic review?
- A clinician concludes that one preventive medication is superior to another because each has evidence of benefit versus placebo. Which interpretation best accords with the systematic review?
- Which set of devices received weak recommendations for acute treatment of migraine in the 2025 International Headache Society guideline?
- Which group received weak recommendations for preventive treatment of migraine using non-invasive neuromodulation?
- A patient asks whether non-invasive neuromodulation devices are established as highly certain migraine treatments. Which response best reflects the International Headache Society guideline?
- What principal methodological limitations did the International Headache Society guideline identify across studies of non-invasive migraine neuromodulation devices?
- Which statement about safety and tolerability of non-invasive neuromodulation devices is consistent with the 2025 guideline summary?
- In the network meta-analysis of tension-type headache prophylaxis, which treatment was reported to reduce monthly headache days compared with placebo at both 4 and 8 weeks?
- Which botulinum toxin A dose was reported as potentially reducing monthly headache days in chronic tension-type headache in the network meta-analysis?
- How should the reported prophylaxis findings for amitriptyline and botulinum toxin A in chronic tension-type headache be interpreted?
- Which statement best describes the study population in the systematic review and network meta-analysis of tension-type headache prophylaxis?
- A review of sex differences in cluster headache found no significant differences between women and men in which group of features?
- Which sex-related finding was reported in the cluster-headache meta-analysis?
- Which statement about comorbidities and lifestyle factors in the cluster-headache sex-differences meta-analysis is accurate?
- What is the most appropriate conclusion about mechanisms underlying sex-related differences reported in cluster headache?
- A patient asks whether Jingtong Granule is an established standard treatment for cervicogenic headache. Which response is best supported by the supplied review?